After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

Italian tyre maker Pirelli is in a risky situation after its Chinese leading shareholder Sinochem rejected a proposal by the ...

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.

The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to ...

Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine ...

Nuvaxovid 由诺瓦瓦克斯与 赛诺菲 （Sanofi）合作开发，后者将根据里程碑协议向诺瓦瓦克斯支付 1.75 亿美元，未来还可能从疫苗销售中支付更多特许权使用费。 该制药商表示，FDA 批准了其针对 Nuvaxovid ...

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at the opening bell Monday.